Exchange: NASDAQ·Updated 03:22 PM EDT
News
all
press releases
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including...
Business Wire
More News
BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for BeOne Medicines Ltd. - Sponsored ADR (ONC) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the second quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: These strong second-quarter results underscore our continued...
Business Wire
Insider Selling: Chan Henry Lee Unloads $337K Of BeOne Medicines Stock
On August 3, a recent SEC filing unveiled that Chan Henry Lee, SVP at BeOne Medicines (NASDAQ:ONC) made an insider sell. What Happened: Lee's recent move involves selling 1,044 shares of BeOne Medicines. Thisread more...
Benzinga
Countdown to BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for BeOne Medicines Ltd. - Sponsored ADR (ONC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.
Zacks
BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines
BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a $300 million expansion of its flagship clinical and commercial-stage manufacturing and research and development center at the Princeton West Innovation Campus in Hopewell, New Jersey...
Business Wire
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating foundational BTK inhibitor BRUKINSA (zanubrutinib) plus rituximab versus bendamustine plus...
Business Wire
Insider Decision: Henry Chan Lee Offloads $156K Worth Of BeOne Medicines Stock
On June 18, a recent SEC filing unveiled that Henry Chan Lee, SVP at BeOne Medicines (NASDAQ:ONC) made an insider sell. What Happened: Lee's decision to sell 590 shares of BeOne Medicines was revealed in a Form 4read more...
Benzinga
President and COO At BeOne Medicines Sells $361K Of Stock
It was reported on June 18, that Xiaobin Wu, President and COO at BeOne Medicines (NASDAQ:ONC) executed a significant insider sell, according to an SEC filing. What Happened: Wu opted to sell 1,357 shares of BeOneread more...
Benzinga
Insider Selling: JOHN OYLER Unloads $980K Of BeOne Medicines Stock
Revealing a significant insider sell on June 18, JOHN OYLER, Chief Executive Officer at BeOne Medicines (NASDAQ:ONC), as per the latest SEC filing. What Happened: OYLER's recent move involves selling 3,693 shares ofread more...
Benzinga

Advertisement|Remove ads.